November 5, 2025
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase…
Pharmaceuticals, Biotechnology and Life Sciences
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase…
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (Euronext:…
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855),…
Reference is made to the stock exchange announcement made by Zelluna ASA (the “Company”) on 3 November 2025 regarding the…
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855),…
Reference is made to the private placement (the “Private Placement”) and the retail offering through PrimaryBid (the “PrimaryBid Offering”) announced by…
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on…
Successful private placement and retail offering – Zelluna ASA raises NOK 58 million to advance the world’s first “off-the-shelf” TCR-NK…
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action — — Lead candidate…
Investor webcast to be held on Monday November 3, 2025 at 8:00 am ESTHAYWARD, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE)…